SCHEMBL3923353

SCHEMBL3923353

CC(=O)/C=N/Nc1ccc(F)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
MPO P05164 3/20 0.45
GAA P10253 2/20 0.45
ALDH1A1 P00352 5/20 0.43
KDM4E B2RXH2 3/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TGM2 P21980 1/20 0.42
MAPK1 P28482 1/20 0.41
NOX1 Q9Y5S8 1/20 0.41
ALOX12 P18054 1/20 0.40
AHR P35869 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3923354 1.00 MEN1 (0.47) MEN1KMT2AMPOGAAALDH1A1
SCHEMBL15947014 0.83 MEN1 (0.49) MEN1KMT2AMPOGAAALDH1A1
SCHEMBL15939088 0.83 MEN1 (0.49) MEN1KMT2AMPOGAAALDH1A1
SCHEMBL15939086 0.83 MEN1 (0.49) MEN1KMT2AMPOGAAALDH1A1
SCHEMBL27676492 0.82 MPO (0.48) MEN1KMT2AMPOGAAALDH1A1
SCHEMBL20133846 0.82 MPO (0.48) MEN1KMT2AMPOGAAALDH1A1
SCHEMBL16283580 0.81 RAB9A (0.47) MEN1KMT2AGAAALDH1A1LMNA
SCHEMBL28515911 0.81 GAA (0.47) MEN1KMT2AGAAALDH1A1LMNA
SCHEMBL28514002 0.81 RAB9A (0.47) MEN1KMT2AGAAALDH1A1LMNA
SCHEMBL1144417 0.81 NOX1 (0.54) MEN1KMT2AGAAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE GAUDINO JOHN 2011-03-03 US disclosed
EP-2032538-A2 QUINOLINE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2009-03-11 EP disclosed
WO-2007146824-A2 QUINOLINE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE TK1, ABL1, ROR1 MEN1 853/4885KMT2A 3205/4885MPO 3780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.